Nektar Therapeutics to Post FY2022 Earnings of ($0.67) Per Share, Jefferies Group Forecasts (NKTR)

Nektar Therapeutics (NASDAQ:NKTR) – Stock analysts at Jefferies Group issued their FY2022 earnings per share (EPS) estimates for shares of Nektar Therapeutics in a research report issued to clients and investors on Tuesday. Jefferies Group analyst D. Steinberg forecasts that the biopharmaceutical company will post earnings of ($0.67) per share for the year. Jefferies Group has a “Buy” rating and a $88.00 price target on the stock.

A number of other research analysts also recently issued reports on the company. Zacks Investment Research upgraded Nektar Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday. Canaccord Genuity reiterated a “buy” rating and set a $80.00 target price (up previously from $50.00) on shares of Nektar Therapeutics in a report on Wednesday, January 10th. Canaccord Genuity Group upped their target price on Nektar Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a report on Wednesday, November 15th. Roth Capital set a $45.00 target price on Nektar Therapeutics and gave the stock a “buy” rating in a report on Monday, November 13th. Finally, Mizuho upped their target price on Nektar Therapeutics from $30.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, November 14th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have assigned a buy rating to the stock. Nektar Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $42.50.

Shares of Nektar Therapeutics (NASDAQ NKTR) traded up $0.76 during trading hours on Wednesday, reaching $70.16. The company had a trading volume of 1,430,416 shares, compared to its average volume of 2,260,000. Nektar Therapeutics has a 52 week low of $11.41 and a 52 week high of $75.33. The stock has a market cap of $11,050.00, a P/E ratio of -98.82 and a beta of 1.81. The company has a debt-to-equity ratio of 2.91, a quick ratio of 3.99 and a current ratio of 4.14.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.16. Nektar Therapeutics had a negative return on equity of 190.68% and a negative net margin of 42.08%. The company had revenue of $152.90 million for the quarter, compared to the consensus estimate of $126.50 million. During the same quarter in the previous year, the business earned ($0.32) EPS. Nektar Therapeutics’s revenue was up 321.2% compared to the same quarter last year.

Several institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. boosted its position in shares of Nektar Therapeutics by 0.9% in the 2nd quarter. BlackRock Inc. now owns 20,221,479 shares of the biopharmaceutical company’s stock worth $395,330,000 after purchasing an additional 185,933 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Nektar Therapeutics by 3.0% in the 2nd quarter. Vanguard Group Inc. now owns 14,009,894 shares of the biopharmaceutical company’s stock worth $273,893,000 after purchasing an additional 401,914 shares in the last quarter. State Street Corp boosted its position in shares of Nektar Therapeutics by 11.3% in the 2nd quarter. State Street Corp now owns 4,408,270 shares of the biopharmaceutical company’s stock worth $86,179,000 after purchasing an additional 447,023 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of Nektar Therapeutics by 87.8% in the 3rd quarter. Janus Henderson Group PLC now owns 3,329,281 shares of the biopharmaceutical company’s stock worth $79,903,000 after purchasing an additional 1,556,352 shares in the last quarter. Finally, Northern Trust Corp boosted its position in shares of Nektar Therapeutics by 7.2% in the 2nd quarter. Northern Trust Corp now owns 1,937,352 shares of the biopharmaceutical company’s stock worth $37,877,000 after purchasing an additional 130,294 shares in the last quarter. 96.01% of the stock is currently owned by hedge funds and other institutional investors.

In other news, Director Christopher A. Kuebler sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $58.66, for a total value of $1,759,800.00. Following the sale, the director now directly owns 70,500 shares of the company’s stock, valued at approximately $4,135,530. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Stephen K. Doberstein sold 396,323 shares of the business’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $29.00, for a total value of $11,493,367.00. Following the completion of the sale, the senior vice president now directly owns 52,016 shares in the company, valued at $1,508,464. The disclosure for this sale can be found here. Insiders have sold a total of 614,017 shares of company stock worth $20,587,527 in the last quarter. Company insiders own 6.10% of the company’s stock.

WARNING: This piece of content was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.com-unik.info/2018/01/18/nektar-therapeutics-to-post-fy2022-earnings-of-0-67-per-share-jefferies-group-forecasts-nktr.html.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit